Previous reports indicated that HDAC inhibitors exhibit anti-inflammatory properties, and might play a beneficial role in the treatment of inflammatory diseases, such as ulcerative colitis, lupus erythematosus and hepatic injury [14,30-32]. This evidence concerns the gene HDAC9 and lupus erythematosus.